|
NO2694640T3
(enExample)
*
|
2011-04-15 |
2018-03-17 |
|
|
|
EP2729180B1
(en)
|
2011-07-08 |
2019-01-23 |
The University of North Carolina At Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
|
BR112015022588A2
(pt)
|
2013-03-14 |
2017-07-18 |
Newlink Genetics Corp |
composto, composição farmacĂȘutica, e, mĂ©todo para tratamento de imunossupressĂŁo em um indivĂduo
|
|
EA201591610A1
(ru)
*
|
2013-03-14 |
2015-12-30 |
ĐŃŃаЎДĐČ Đ€Đ°ŃĐŒĐ° ĐŃаĐčĐČĐžŃ ĐŃĐŽ. |
ĐĐœĐłĐžĐ±ĐžŃĐŸŃŃ ĐșĐžĐœŃŃĐ”ĐœĐžĐœĐŸĐČĐŸĐłĐŸ ĐżŃŃĐž
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN103382187B
(zh)
*
|
2013-08-06 |
2015-06-03 |
俥ćźçç©ć»èŻïŒäžæ”·ïŒæéć
Źćž |
äžç§3-æ°Ż-7(5)-æșŽèŻćč¶ćŒæ¶ćçćææčæł
|
|
EA201990240A1
(ru)
|
2013-12-24 |
2019-06-28 |
ĐŃĐžŃŃĐŸĐ»-ĐаДŃŃ ĐĄĐșĐČОбб ĐĐŸĐŒĐżĐ°ĐœĐž |
ĐĐŸĐČŃĐ” ŃŃĐžŃĐžĐșлОŃĐ”ŃĐșОД ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐČ ĐșаŃĐ”ŃŃĐČĐ” ĐżŃĐŸŃĐžĐČĐŸŃаĐșĐŸĐČŃŃ
ŃŃДЎŃŃĐČ
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
ES2901705T3
(es)
|
2014-06-06 |
2022-03-23 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
|
|
KR20170044144A
(ko)
|
2014-09-05 |
2017-04-24 |
ë©ë„ŽíŹ íí
íž êČì ëČ í |
ì ìčëŁë„Œ ìí ìžëìëŻŒ-2,3-ëì„ìêČëì (ido) êžžíì ëĄì ìíŽëĄí„ì€-ìíž ìčíë ëìì- ë° ížëŠŹìì-ížëŠŹìíŽëŠ íí©ëŹŒ
|
|
GB201417369D0
(en)
*
|
2014-10-01 |
2014-11-12 |
Redx Pharma Ltd |
Compounds
|
|
GB201418300D0
(en)
*
|
2014-10-15 |
2014-11-26 |
Redx Pharma Ltd |
Compounds
|
|
CA3220466A1
(en)
|
2014-10-29 |
2016-05-06 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for mt1-mmp
|
|
SI3221363T1
(sl)
|
2014-11-21 |
2020-09-30 |
Bristol-Myers Squibb Company |
Protitelesa proti CD73 in njihova uporaba
|
|
US10525035B2
(en)
|
2014-12-18 |
2020-01-07 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
CA2971732A1
(en)
|
2014-12-23 |
2016-06-30 |
Bristol-Myers Squibb Company |
Antibodies to tigit
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
CN105884828A
(zh)
*
|
2015-02-16 |
2016-08-24 |
äžæ”·èżȘèŻșć»èŻç§ææéć
Źćž |
ć€çŻććç©ăć
¶èŻç©ç»ćç©ććșçš
|
|
KR20170122799A
(ko)
|
2015-03-02 |
2017-11-06 |
늏êČ íë§ìí°ìčŒì€, ìžíŹ. |
TGF-ÎČ ì”ì ì
|
|
US10399933B2
(en)
|
2015-04-03 |
2019-09-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
KR20170137165A
(ko)
*
|
2015-04-10 |
2017-12-12 |
ëČ ìŽì§ ìí°ë |
ìžëìëŻŒ ë°/ëë ížëŠœí í 2,3-ëì„ìêČëìì ëĄì ì ê·í 5 ëë 8-ìčíë ìŽëŻžë€ìĄ°[1,5-a]íŒëŠŹë
|
|
EP3283488A4
(en)
*
|
2015-04-12 |
2018-10-24 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as ido and tdo inhibitors
|
|
HUE053903T2
(hu)
|
2015-04-13 |
2021-07-28 |
Five Prime Therapeutics Inc |
KombinĂĄciĂłs terĂĄpia rĂĄk ellen
|
|
AU2016250976B2
(en)
|
2015-04-21 |
2020-02-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Imidazo isoindole derivative, preparation method therefor and medical use thereof
|
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
WO2016183115A1
(en)
|
2015-05-12 |
2016-11-17 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
SG10202008304TA
(en)
|
2015-05-29 |
2020-10-29 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
|
GB2548542A
(en)
*
|
2015-06-16 |
2017-09-27 |
Redx Pharma Plc |
Compounds
|
|
CN106256830B
(zh)
*
|
2015-06-18 |
2019-03-08 |
æéœæ”·ćèŻäžæéć
Źćž |
äžç§æ°ä»Łçidoæć¶ććć
¶ć¶ć€æčæłćçšé
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
CN105037371A
(zh)
*
|
2015-06-30 |
2015-11-11 |
è„żćć€§ćŠ |
äžç§æ°ä»ŁçćČćèș-2,3-ćć æ°§é
¶æć¶ć
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
CN116196426A
(zh)
|
2015-07-16 |
2023-06-02 |
çŸæŹ§èŻæČ»çæéć
Źćž |
æČ»ççççç»ćç©ćæčæł
|
|
MX2018001014A
(es)
|
2015-07-24 |
2018-05-23 |
Newlink Genetics Corp |
Sales y profarmacos de 1-metil-d-triptofano.
|
|
WO2017019757A1
(en)
|
2015-07-28 |
2017-02-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
JP2018525415A
(ja)
|
2015-08-25 |
2018-09-06 |
ăăȘăčăă«âăă€ă€ăŒăș ăčăŻă€ă ă«ăłăăăŒïŒąïœïœïœïœïœïœâïŒïœïœ
ïœïœ ïŒłïœïœïœïœïœ ïŒŁïœïœïœïœïœïœ |
ïœïœăăŒăżććźčäœăąăłăżăŽăăčă
|
|
CN106478634B
(zh)
*
|
2015-09-01 |
2020-05-22 |
ć°ćć»èŻç§æ(æ±è„ż)æéć
Źćž |
çš ććȘćććç©ăć
¶ć¶ć€æčæłăèŻç©ç»ćç©ćçšé
|
|
WO2017075341A1
(en)
*
|
2015-10-29 |
2017-05-04 |
Scifluor Life Sciences, Inc. |
Fused imidazole derivatives as ido/tdo inhibitors
|
|
JP6936221B2
(ja)
|
2015-11-02 |
2021-09-15 |
ăăĄă€ă ăă©ă€ă ă»ă©ăă„ăŒăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă |
ïŒŁïœïŒïŒçްèć€ăăĄă€ăłăăȘăăăăăšăăăæČ»çă§ăźăăăăźäœżçš
|
|
WO2017080934A1
(en)
*
|
2015-11-09 |
2017-05-18 |
F. Hoffmann-La Roche Ag |
Screening assay to identify id01 and/or tdo modulators
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
JP7349787B2
(ja)
|
2015-11-23 |
2023-09-25 |
ăăĄă€ăŽ ăă©ă€ă ă»ă©ăă„ăŒăăŁăŻăč ă€ăłăŻ |
çæČ»çă«ăăăïœïœïœïœïŒé»ćźłć€ćçŹăŸăăŻć
ç«ćșæżć€ăšăźç”ăżćăă
|
|
US10450318B2
(en)
|
2015-12-15 |
2019-10-22 |
Bristol-Myers Squibb Company |
CXCR4 receptor antagonists
|
|
JP7227005B2
(ja)
*
|
2015-12-24 |
2023-02-21 |
ăžă§ăăłăăăŻïŒ ă€ăłăłăŒăăŹă€ăăă |
ïœïœïŒé»ćźłć€
|
|
CN107056785B
(zh)
*
|
2016-01-02 |
2021-06-22 |
æć·è±ćć»èŻç§ææéć
Źćž |
äœäžșidoćtdoæć¶ćçæçŻććç©
|
|
EP3400226A1
(en)
|
2016-02-02 |
2018-11-14 |
Emcure Pharmaceuticals Limited |
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
|
US10487088B2
(en)
|
2016-02-19 |
2019-11-26 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Tricyclic compound serving as immunomodulator
|
|
EP3416725A1
(en)
|
2016-02-19 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
CN108884104B
(zh)
*
|
2016-02-19 |
2021-01-15 |
æŁć€§ć€©æŽèŻäžéćąèĄä»œæéć
Źćž |
äœäžșć
ç«è°èćçäžćč¶çŻććç©
|
|
WO2017149469A1
(en)
|
2016-03-03 |
2017-09-08 |
Emcure Pharmaceuticals Limited |
Heterocyclic compounds useful as ido and/or tdo modulators
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
í-cd73 íìČŽìì ìĄ°í© ìëČ
|
|
SG11201808821WA
(en)
|
2016-04-18 |
2018-11-29 |
Celldex Therapeutics Inc |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
CN105732643A
(zh)
*
|
2016-04-18 |
2016-07-06 |
èć·ć€§ćŠ |
äžç§ć¶èç©ăć
¶ć¶ć€æčæłććšć¶ć€idoé
¶æć¶ććéçŸäœæçèŻç©äžçćșçš
|
|
CN107312005B
(zh)
*
|
2016-04-27 |
2021-12-17 |
äžæ”·çż°æŁźçç©ć»èŻç§ææéć
Źćž |
ć
·æido/tdoæć¶æŽ»æ§ççš ććȘćèĄçç©ćć
¶ć¶ć€æčæłććșçš
|
|
CN109348714A
(zh)
|
2016-05-04 |
2019-02-15 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ćČćèș2,3-ćć æ°§é
¶çæć¶ććć
¶äœżçšæčæł
|
|
KR20190004743A
(ko)
|
2016-05-04 |
2019-01-14 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
ìžëìëŻŒ 2,3-ëì„ìêČëì ì ì”ì ì ë° ê·žì ìŹì© ë°©ëČ
|
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR20190003687A
(ko)
|
2016-05-04 |
2019-01-09 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
ìžëìëŻŒ 2,3-ëì„ìêČëì ì ì”ì ì ë° ê·žì ìŹì© ë°©ëČ
|
|
KR20190003686A
(ko)
|
2016-05-04 |
2019-01-09 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
ìžëìëŻŒ 2,3-ëì„ìêČëì ì ì”ì ì ë° ê·žì ìŹì© ë°©ëČ
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4ć»èŻć
Źćž |
çšäșé¶èçœéè§Łçèșèżæ„çc3-æäșé
°äșèșéè§Łćłćźćäœ
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN105902542A
(zh)
*
|
2016-05-16 |
2016-08-31 |
ćŒ éł |
äžç§ć¶èç©ćšć¶ć€æČ»çćżèĄçźĄçŸç
èŻç©äžçćșçš
|
|
CN107383012B
(zh)
*
|
2016-05-16 |
2021-09-28 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
ć«äșçŻçćȘćéèĄçç©
|
|
CN107556316B
(zh)
*
|
2016-06-30 |
2021-11-12 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćèĄçç©
|
|
WO2017198159A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćèĄçç©
|
|
CN106957318B
(zh)
*
|
2016-05-19 |
2019-12-10 |
äžćœç§ćŠéąäžæ”·ææșććŠç ç©¶æ |
çš ćć€çŻćČććććç©ăć
¶ć¶ć€æčæłăèŻç©ç»ćç©ććșçš
|
|
JP7090034B2
(ja)
|
2016-05-20 |
2022-06-23 |
ă¶ ăŠăăăŒă·ă㣠ăȘă ă·ă«ăŽ |
ććŠçæłăæšççæłăć
ç·ććŠçæłăć
ç«çæłćăłăăăăźä»»æăźç”ăżćăăăźăăăźăăçČć
|
|
AR108586A1
(es)
|
2016-06-10 |
2018-09-05 |
Lilly Co Eli |
Compuestos de 2,3-dihidro-1h-indol
|
|
CN107488179B
(zh)
*
|
2016-06-11 |
2024-06-07 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
㫿Ą„çŻçćȘćéèĄçç©
|
|
CN107556315B
(zh)
*
|
2016-06-30 |
2021-08-31 |
éČćć¶èŻéćąèĄä»œæéć
Źćž |
ć«ćć
çŻçćȘćèĄçç©
|
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
CN107663159A
(zh)
*
|
2016-07-29 |
2018-02-06 |
äžæ”·èżȘèŻșć»èŻç§ææéć
Źćž |
ć€çŻććç©ăć
¶èŻç©ç»ćç©ććșçš
|
|
CN107698594A
(zh)
*
|
2016-08-09 |
2018-02-16 |
èć·ćœćĄć»èŻç§ææéć
Źćž |
ćČćèș2ïŒ3âćć æ°§é
¶æć¶ććć
¶ćšèŻćŠäžççšé
|
|
US11351164B2
(en)
|
2016-08-26 |
2022-06-07 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2018045966A1
(zh)
*
|
2016-09-12 |
2018-03-15 |
ćčżć·ćż
èŽçčć»èŻææŻæéć
Źćž |
ć«ćȘćçš ćäžçŻç±»ććç©ćć
¶ćșçš
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
çŸćæźé·èŸèŻć
Źćž |
çšæŒïœïœïœćïœïœïœèȘżçŻäčććç©ćæčæłä»„ćć
¶é©æç
|
|
CN109952300B
(zh)
|
2016-09-24 |
2022-01-18 |
çŸæ”ç„ć·æéć
Źćž |
5æ8-ć代çćȘććč¶[1,5-a]ćĄć¶
|
|
AU2017343780B2
(en)
|
2016-10-13 |
2023-08-31 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
TW201815793A
(zh)
*
|
2016-10-21 |
2018-05-01 |
æ±èæçé«è„èĄä»œæéć
Źćž |
äžçšźćȘć䞊ç°ćČćéĄèĄçç©çééąéčŒçç”æ¶ćœąćŒćć
¶èŁœćæčæł
|
|
TW201815417A
(zh)
*
|
2016-10-21 |
2018-05-01 |
èć·çèżȘäșçç©é«è„æéć
Źćž |
ïœïŒïŒæé«èïœïœïœæć¶ćèŻććšèŁœćæè
«ç€çè„ç©äžççšé
|
|
WO2018083635A2
(en)
|
2016-11-04 |
2018-05-11 |
Auckland Uniservices Limited |
Tricyclic heterocyclic derivatives and uses thereof
|
|
CN106474468B
(zh)
*
|
2016-11-23 |
2020-03-27 |
äžćœć»ćŠç§ćŠéąć»ćŠçç©ćŠç ç©¶æ |
äžç§ć€ćäœćăć«èŻ„ć€ćäœćçç«èćç«èçć¶ć€æčæł
|
|
WO2018106579A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Albert Einstein College Of Medicine, Inc. |
Drug targeting of human indoleamine 2,3-dioxygenase
|
|
US10604529B2
(en)
|
2016-12-20 |
2020-03-31 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
|
|
PE20191541A1
(es)
|
2016-12-22 |
2019-10-23 |
Calithera Biosciences Inc |
Composiciones y metodos para inhibir la accion de la arginasa
|
|
CN108239091B
(zh)
*
|
2016-12-26 |
2021-08-13 |
äžćœć»ćŠç§ćŠéąèŻç©ç ç©¶æ |
1-çŻć·±ćș-2-(5H-ćȘć[5,1-a]ćŒćČć)äčćș-1-é
źçæć
|
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
|
JP2020506895A
(ja)
|
2017-01-17 |
2020-03-05 |
ăăŒă ăȘă ăŹăžă§ăłă, ă¶ ăŠăăăŒă·ă㣠ăȘă ăăă”ăč ă·ăčăă Board Of Regents, The University Of Texas System |
ă€ăłăăŒă«ăąăăłïŒïŒïŒâăžăȘăă·ăČăăŒăŒăăăłïŒăŸăăŻăăȘăăăăĄăłăžăȘăă·ăČăăŒăŒăźé»ćźłć€ăšăăŠæçšăȘććç©
|
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
æicosäżæćæé«ćć
¶çšé
|
|
SG11201909710XA
(en)
|
2017-04-21 |
2019-11-28 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
|
ES2899616T3
(es)
|
2017-04-28 |
2022-03-14 |
Five Prime Therapeutics Inc |
Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
|
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN107176956B
(zh)
*
|
2017-05-31 |
2019-11-12 |
æéœæ”·ćéèŻäžæéć
Źćž |
äžç§idoæć¶ćććç©ăèŻçšç»ćç©ăçšé
|
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
WO2019005559A1
(en)
|
2017-06-28 |
2019-01-03 |
Genentech, Inc. |
INHIBITORS OF TDO2 AND IDO1
|
|
US11827639B2
(en)
|
2017-06-28 |
2023-11-28 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
|
US11236049B2
(en)
|
2017-06-30 |
2022-02-01 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of IDO inhibitors
|
|
KR102709265B1
(ko)
|
2017-07-28 |
2024-09-23 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íìì ëĄìì ìíŽëŠ ëëŽíŽë ì€í°ë
|
|
CN111194232B
(zh)
|
2017-08-02 |
2023-01-31 |
èć ć„ć€§ćŠ |
çșłç±łçș§é㱿æșć±ćé㱿æșçșłç±łç
|
|
US11261214B2
(en)
|
2017-08-04 |
2022-03-01 |
Bicycletx Limited |
Bicyclic peptide ligand specific for CD137
|
|
CN109983019B
(zh)
*
|
2017-08-08 |
2021-12-21 |
æ±èæçć»èŻèĄä»œæéć
Źćž |
äžç§ćȘććč¶ćŒćČćç±»èĄçç©çć¶ć€æčæł
|
|
CN109384791B
(zh)
*
|
2017-08-09 |
2020-09-11 |
æ±èæçć»èŻèĄä»œæéć
Źćž |
äžç§ćȘććč¶ćŒćČćç±»èĄçç©æžžçŠ»çą±çæ¶ććć
¶ć¶ć€æčæł
|
|
EP3668880B1
(en)
|
2017-08-17 |
2021-10-06 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
CA3073051A1
(en)
|
2017-08-17 |
2019-02-21 |
Ikena Oncology, Inc. |
Ahr inhibitors and uses thereof
|
|
EP3670518A4
(en)
|
2017-08-18 |
2021-01-06 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
TRICYCLIC COMPOUND CRYSTALS
|
|
JP7209697B2
(ja)
|
2017-08-31 |
2023-01-20 |
ăăȘăčăă«ïŒăă€ă€ăŒăș ăčăŻă€ă ă«ăłăăăŒ |
æçć€ăšăăŠăźç°ç¶ăžăăŻăŹăȘăă
|
|
EP3676279B1
(en)
|
2017-08-31 |
2021-12-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
EP3676277A1
(en)
|
2017-08-31 |
2020-07-08 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CN107501272B
(zh)
*
|
2017-09-05 |
2020-03-31 |
äžćœèŻç§ć€§ćŠ |
ćȘććč¶ćŒćČćç±»ido1æć¶ćăć
¶ć¶ć€æčæłććșçš
|
|
US20200261414A1
(en)
|
2017-09-14 |
2020-08-20 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of cancer
|
|
EP3684365A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND USES OF SUCH
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
EP3694867A1
(en)
|
2017-10-10 |
2020-08-19 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
KR102747388B1
(ko)
|
2017-10-16 |
2024-12-26 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íìì ëĄìì ìíŽëŠ ëëŽíŽë ì€í°ë
|
|
JP7306634B2
(ja)
|
2017-10-19 |
2023-07-11 |
äžèŹç€ŸćŁæłäșșăăĄă«ăăăŹăŒăăăžă§ăŻăæŻæŽæ©æ§ |
ïœïœïŒïœïœïœé»ćźłć€
|
|
KR20200074214A
(ko)
|
2017-11-01 |
2020-06-24 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
ìì ìčëŁíëë° ìŹì©íêž° ìí 멎ììê·č íšë„ìì© íìČŽ
|
|
US11166959B2
(en)
|
2017-11-06 |
2021-11-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as HPK1 inhibitors
|
|
CN111386114A
(zh)
|
2017-11-25 |
2020-07-07 |
çŸæ”ç„ć·æéć
Źćž |
äœäžșćČćèș2,3-ćć æ°§é
¶çéæ©æ§æć¶ćçæ°éąèŻćč¶ćȘć
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11306149B2
(en)
|
2017-12-27 |
2022-04-19 |
Bristol-Myers Squibb Company |
Anti-CD40 antibodies and uses thereof
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN111886255B
(zh)
|
2018-01-12 |
2025-04-04 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ætim3æäœćć
¶çšé
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
JP7217279B2
(ja)
|
2018-01-15 |
2023-02-02 |
ă€ăăŒă·ăą ăăĄăŒăă·ă„ăŒăăŁă«ă«ăș ăȘăăăă |
ă€ăłăăŒă«ăąăăł ïŒïŒïŒïŒăžăȘăă·ăČăăŒăŒćăłïŒćăŻăăȘăăăăĄăł ïŒïŒïŒïŒăžăȘăă·ăČăăŒăŒăźé»ćźłć€
|
|
CN111247119B
(zh)
*
|
2018-01-19 |
2023-02-03 |
ćć·ç§äŒŠćæł°çç©ć»èŻèĄä»œæéć
Źćž |
èç±»ćèç±»èĄçç©ăć
¶ć¶ć€æčæłćć
¶ćšć»èŻäžçćșçš
|
|
US10793563B2
(en)
|
2018-01-29 |
2020-10-06 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
ë©ë„ŽíŹ íí
íž êČì ëČ í |
Gcn2 ì”ì ì ë° ìŽì ì©ë
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
MX2020008791A
(es)
|
2018-02-23 |
2021-01-08 |
Bicycletx Ltd |
Ligandos de peptidos biciclicos multimericos.
|
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íìì ëĄìì ìíŽëŠ ëëŽíŽë ì€í°ë
|
|
EP3768666A1
(en)
|
2018-03-20 |
2021-01-27 |
Plexxikon Inc. |
Compounds and methods for ido and tdo modulation, and indications therefor
|
|
AU2019239747A1
(en)
|
2018-03-21 |
2020-10-08 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
CN112218657A
(zh)
|
2018-04-12 |
2021-01-12 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
Cd73æźæćæäœćpd-1/pd-l1èœŽæźæćæäœçæçç»ćçæł
|
|
JP2021522211A
(ja)
|
2018-04-16 |
2021-08-30 |
ăąăȘăŒăș ă»ă©ăă„ăŒăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă |
ïœïŒé»ćźłć€ăăăłăăźäœżçš
|
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
ES2950007T3
(es)
|
2018-06-27 |
2023-10-04 |
Bristol Myers Squibb Co |
Compuestos de naftiridinona Ăștiles como activadores de cĂ©lulas T
|
|
BR112020026681A2
(pt)
|
2018-06-27 |
2021-04-06 |
Bristol-Myers Squibb Company |
Compostos naftiridinona substituĂdos Ășteis como ativadores de cĂ©lula t
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
EP3820904A2
(en)
|
2018-07-09 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ĂĄcido
|
|
US11046649B2
(en)
|
2018-07-17 |
2021-06-29 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
US12145927B2
(en)
|
2018-07-23 |
2024-11-19 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
EP3858813A4
(en)
*
|
2018-09-27 |
2022-06-22 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
|
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
æł°æŽæŻæČ»çć
Źćž |
ælapæäœćäœćć
¶çšé
|
|
KR20210092769A
(ko)
|
2018-11-16 |
2021-07-26 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
í-nkg2a íìČŽ ë° ê·žì ì©ë
|
|
SG11202105424PA
(en)
|
2018-11-30 |
2021-06-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
JP7684947B2
(ja)
|
2019-03-19 |
2025-05-28 |
ăăłăă·ăȘ ăăȘăă ă€ăłăčăăŁăă„ă ăăŁăłăăčăăŁăŹă·ăȘ ăȘăłăłăăžă« ă ăă« ăšăăăł |
çăźæČ»çăźăăăźäœ”çšçæł
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
SG11202110829YA
(en)
|
2019-04-05 |
2021-10-28 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
TW202108559A
(zh)
|
2019-05-31 |
2021-03-01 |
çŸćé«èŻçŽè
«ç€ćžć
Źćž |
Teadæć¶ććć
¶çšé
|
|
EP3997083A1
(en)
|
2019-07-11 |
2022-05-18 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
|
|
EP4027995A4
(en)
|
2019-09-13 |
2023-08-23 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND THEIR APPLICATIONS
|
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
KR20220103753A
(ko)
|
2019-11-19 |
2022-07-22 |
ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í
컎íŒë |
íŹëŠŹì€ì€ ëšë°±ì§ì ì”ì ì ëĄì ì ì©í íí©ëŹŒ
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
CA3159071A1
(en)
|
2019-11-26 |
2021-06-03 |
Tamar I. ROSENBAUM |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
CN111333653A
(zh)
*
|
2019-12-16 |
2020-06-26 |
ć±±äžć€§ćŠ |
äžç§icdèŻ±ćŻŒć-idoæć¶ćçŒćç©ćć¶ć€æčæłäžćșçš
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
MX2022007576A
(es)
|
2019-12-17 |
2022-09-23 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicĂclicos sustituidos Ăștiles como activadores de cĂ©lulas t
|
|
IL294273A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds are useful as t-cell activators
|
|
IL294150A
(en)
|
2019-12-23 |
2022-08-01 |
Kymera Therapeutics Inc |
Smarca joints and their uses
|
|
BR112022012222A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Derivados de piperazina substituĂdos Ășteis como ativadores de cĂ©lulas t
|
|
IL294269A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
ES3038401T3
(en)
|
2019-12-23 |
2025-10-13 |
Bristol Myers Squibb Co |
Substituted quinazolinyl compounds useful as t cell activators
|
|
CA3166898A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
BR112022013494A2
(pt)
|
2020-01-07 |
2022-09-13 |
Hifibio Hk Ltd |
Anticorpo anti-galectina-9 e usos do mesmo
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
MX2022011602A
(es)
|
2020-03-19 |
2023-01-04 |
Kymera Therapeutics Inc |
Degradadores de la proteĂna de homĂłlogo de ratĂłn de minuto 2 (mdm2) y usos de los mismos.
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
ç¶ć代äčćŽæ°§ćșç°ćČććććç©
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
çŸćć±éș„æé«çć
Źćž |
Irakéè§Łćäčç”æ¶ć
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
CN111803635B
(zh)
*
|
2020-06-17 |
2023-03-14 |
äžćœć»ćŠç§ćŠéąćșçĄć»ćŠç ç©¶æ |
ć°ććæć¶ććšæČ»çćŒćžéç
æŻæ§èșçäžçćșçš
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
KR20230044480A
(ko)
|
2020-07-30 |
2023-04-04 |
ìčŽìŽë©ëŒ ìëŒíší±ì€ ìžìœíŹë ìŽí°ë |
ëì°ëłìŽ ëŠŒíìą
ì ìčëŁ ë°©ëČ
|
|
IL300537A
(en)
|
2020-08-10 |
2023-04-01 |
Gv20 Therapeutics Llc |
Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
|
|
EP4196792A1
(en)
|
2020-08-17 |
2023-06-21 |
BicycleTX Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
US20230416382A1
(en)
|
2020-10-14 |
2023-12-28 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CN116964050A
(zh)
|
2020-12-16 |
2023-10-27 |
æèšé»çç©æćĄć
Źćž |
ćŻçšäœtç»èæżæŽ»ćçććç©
|
|
AU2021413371A1
(en)
|
2020-12-30 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
é米èŻșçç©ç§ćŠæéć
Źćž |
Gpr84æźæććć
¶çšé
|
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
æäŒŻćŁ«èšéĄżć
Źćž |
Hpk1æźæććć
¶çšé
|
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
AU2022220043A1
(en)
|
2021-02-15 |
2023-08-31 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
AU2022220869A1
(en)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
EP4052705A1
(en)
|
2021-03-05 |
2022-09-07 |
UniversitÀt Basel Vizerektorat Forschung |
Compositions for the treatment of ebv associated diseases or conditions
|
|
US20240091202A1
(en)
|
2021-03-05 |
2024-03-21 |
UniversitÀt Basel |
Compositions for the treatment of ebv associated diseases or conditions
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ăă«ăŒăăȘăłă ăĄăăŁă·ăłăș ăłăŒăăŹă€ă·ă§ăł |
ïŒïœïœïŒïœïŒé»ćźłć€
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
EP4313989A4
(en)
|
2021-03-29 |
2025-03-05 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ă¶ ăȘăŒăžă§ăłă ăȘă ă¶ ăŠăăăŒă·ă㣠ăȘă ă«ăȘăă©ă«ăăą |
ćæćïœïœïœïœïŒă«ćŻŸăăæäœăăăłăăźäœżçš
|
|
MX2023011408A
(es)
|
2021-04-05 |
2024-01-18 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
|
|
AR125298A1
(es)
|
2021-04-06 |
2023-07-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
|
EP4319756A4
(en)
|
2021-04-09 |
2025-02-26 |
Nimbus Clio, Inc. |
CBL-B MODULATORS AND USES THEREOF
|
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
ă€ă±ă ăȘăłăłăăžăŒïŒ ă€ăłăłăŒăăŹă€ăăă |
ïŒïœ
ïœé»ćźłć€ćăłăăźäœżçš
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
AU2022312496A1
(en)
|
2021-07-14 |
2024-02-22 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
|
TW202321238A
(zh)
|
2021-07-15 |
2023-06-01 |
çŸćçșćè„ćć
Źćž |
ïŒïœïœïŒïœïŒæć¶ć
|
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ă㯠ă»ă©ăă„ăŒăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă |
ïœ
ïŒïŒ„é»ćźłć€ćăłăăźäœżçš
|
|
CN118302168A
(zh)
|
2021-10-29 |
2024-07-05 |
ćŻéșŠæć»çć
Źćž |
Irak4éè§Łććć
¶ć¶ć€
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
EP4472967A2
(en)
|
2022-01-31 |
2024-12-11 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP2025503312A
(ja)
|
2022-02-01 |
2025-01-30 |
ăąă«ăăăčă»ăȘăăŹăŒă·ă§ăłășă»ă€ăłăłăŒăăŹă€ăăă |
ïœïœæšçćććç©ăăăłăăźäœżçš
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
IL318576A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
Pyridoxine-substituted GPR84 antagonists and their uses
|
|
KR20250057800A
(ko)
|
2022-08-02 |
2025-04-29 |
늏믞ë ë°ìŽì€ìŹìŽìžìì€ ëŠŹëŻží°ë |
í€í
ëĄì늎 ìčŽëł”ì€ìë§ìŽë ë° êŽë š gpr84 êžžíì ë° ìŽì ì©ë
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
ç棫ć蔫ććæçŸ
èĄä»œć
Źćž |
éç°ćæ°«ć»ććŻèĄçç©
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
MA71728A
(fr)
|
2022-08-11 |
2025-05-30 |
F. Hoffmann-La Roche Ag |
Dérivés bicycliques de tétrahydrothiazépine
|
|
JP2025526727A
(ja)
|
2022-08-11 |
2025-08-15 |
ăšăă»ăăăăłïŒă©ă»ăă·ă„ă»ăąăŻăă§ăłăČăŒă«ă·ăŁăă |
äșç°ćŒăăă©ăăăăăąăŒăăłèȘć°äœ
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116143726B
(zh)
*
|
2022-12-02 |
2024-09-06 |
ćčżć·ćžèçć¶èŻæéć
Źćž |
äžç§çŻçŁ·è
șè·æèŽšçć¶ć€æčæł
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
CN121057732A
(zh)
|
2023-05-08 |
2025-12-02 |
çŸæ¶çŸæœèŽ”ćźć
Źćž |
ç»ć代çèŻćșććé
źććç©
|
|
AU2024269298A1
(en)
|
2023-05-10 |
2025-11-27 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
WO2024249540A1
(en)
|
2023-05-31 |
2024-12-05 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2024264017A2
(en)
|
2023-06-23 |
2024-12-26 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
AR133696A1
(es)
|
2023-09-02 |
2025-10-22 |
Bristol Myers Squibb Co |
Compuestos de fenil oxooxazolil piperidinadiona sustituida
|
|
TW202525792A
(zh)
|
2023-09-13 |
2025-07-01 |
çŸććż
æČ»ćŠ„çŸé
ćČè°·æŻć
Źćž |
ç¶ć代äčćŽæ°§ç°ćČćććșćć¶ïŒïŒïŒïŒïŒäșé
źććç©
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
CN119707950A
(zh)
*
|
2024-12-24 |
2025-03-28 |
æ éĄćžćäșŹć€§ćŠéĄć±±ćșçšçç©ææŻç ç©¶æ |
äžç§çšäșć
ç«èçœé¶ćéè§Łçć”ćäœćć
¶ć¶ć€æčæłććșçš
|